rotavirus vaccine, live, oral, tetravalent

Trade name: RotaShield

Vaccinewithdrawn

Approved

Aug 31, 1998

A rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. These vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of the risk of death among young children due to severe diarrhea. Immunizing babies decreases rates of rotavirus disease among older people and those who have not been immunized. — Wikipedia

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2009 (NCT00757926)

Timeline

1990s

  1. Aug 31, 1998

    Earliest FDA Approval

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • RotavirusImmunity, active

    Rotavirus immunity, active

Approval history

  • withdrawnAug 31, 1998

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • live attenuated tetravalent (g1-g4) bovine-human reassortant rotavirus vaccine
  • rotashield
  • rotavirus serotype 1 reassortant, rotavirus serotype 2 reassortant, rotavirus serotype 3 rhesus, rotavirus serotype 4 reassortant
  • rotavirus serotype g1, serotype g2, serotype g3, serotype g4, serotype p1
  • rotavirus vaccine, live, oral, tetravalent

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01061658Phase 1/Phase 2 (Phase 2)Jul 1, 2010Shantha Biotechnics Limited
NCT01091298Phase 1Apr 1, 2010Shantha Biotechnics Limited
NCT00757926Phase 1/Phase 2 (Phase 2)Sep 1, 2009PATH, Shantha Biotechnics Limited
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Shantha Biotechnics LimitedFor profit3322009
PATHAcademic/Hospital1012009
2 organizations
Page 1 / 1